View Latest Medical and Pharma Bids and Tenders

Conclusion Of Non-Exclusive Discount Agreements Pursuant To Section 130A Paragraph 8/130C Paragraph 1 Sgb V For Medicinal Products Containing The Active Ingredient Olanzapine (N05Ah03), Without Solid Oral Dosage Forms As Part Of A So-Called Open-House Model.

Pharmaceutical Discount Agreements For Various Active Ingredients Within The Framework Of An Open-House Procedure

Open House Original Discount Agreements 2024-05 - Olanzapine Embonate

Conclusion Of A Non-Exclusive Discount Agreement Pursuant To Section 130A Paragraph 8 Sgb V For The Active Ingredient Olanzapine (Excl. Dafo. For The Production Of A Depot - Isu, Atc N05Ah03 (Obo) For The Period 01.08.24 - 31.07.26

Olanzapine 10Mg Tablet Or Dispersible Tablet, Po, Impresent, Call I, 1000936847-08-31

Delivery Of A Medicinal Product With The Active Ingredient Olanzapin

Provision Of Exclusive Medicines: Parenteral Olanzapine (Zyprexa), Ramucirumab (Cyramza), Abemaciclib (Verzenios) And Pemetrexed (Alimta). 3Rd Extension P.N.S.P. 21/2020.

Medicines Olanzapine And Quetiapine

Delivery Of A Medicinal Product With The Active Ingredient Olanzapine

Medicinal Product With The Active Ingredient "Olanzapine", Strength 5 Mg, 10 Mg